

DPC **News Release**

Diagnostic Products Corporation Announces Record Fourth Quarter and Full Year 2005 Results

LOS ANGELES, CA (*February 10, 2006*) Diagnostic Products Corporation (NYSE:DP) today reported fourth quarter sales of \$123.8 million, a 4% increase over the fourth quarter of 2004. Earnings were \$13.1 million, or \$.43 per diluted share, up 17% from \$11.1 million or \$.37 reported for the fourth quarter of 2004. The Brazilian Real strengthened relative to the dollar while the Euro weakened, and the net effect of foreign currency movements was a 2% decrease in sales. Domestic sales increased 8% to \$38.2 million while international sales grew at 3%.

Sales of IMMULITE products grew 5% over the fourth quarter of 2004. IMMULITE product line sales reached \$114.0 million for the quarter. IMMULITE reagent sales increased 6% this quarter over the fourth quarter of 2004 to \$95.4 million, and IMMULITE instrument and service revenue increased by 5% to \$18.6 million. Sales of RIA products were \$5.1 million, a 13% decline from last year's fourth quarter. Sales of other products were \$4.7 million, the same as the fourth quarter last year.

Sales for the year ended December 31, 2005 were \$481.1 million, an 8% increase over the \$446.8 million recorded in 2004. Net income for the year was \$67.2 million, or \$2.23 per diluted share, versus \$61.7 million, or \$2.06, per share last year. The Brazilian Real strengthened relative to the dollar and the Euro weakened slightly, the net effect of foreign currency was a 2% increase in sales.

For the year, IMMULITE product line sales were \$440.4 million, compared to \$404.9 million in 2004, an increase of 9%. Sales of the mature RIA product line were \$21.4 million for the year, down 11% from last year. Sales of other products were \$19.3 million for the year, up from \$17.8 million in 2004. The Company shipped a total of 256 IMMULITE Instruments in the fourth quarter, including 184 IMMULITE 2000's and 2500's. The total number of IMMULITEs shipped is now over 10,900.

“While reagent sales were disappointing we are very pleased with the number of instruments shipped,” said Michael Ziering, CEO of DPC. “We believe the strong shipments coupled with the release of certain key assays put us in a very good position going forward.”

Diagnostic Products Corporation, founded in 1971, is a global leader dedicated to immunodiagnosics. DPC's product menu includes over 75 immunoassays and more than 375 specific allergens and allergy panels. In addition, DPC addresses the chemistry and laboratory automation testing needs of its customers through partnerships with manufacturers of chemistry systems and reagents. The combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC also designs and

manufactures automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries. Additional Company information can be found on DPC's website at www.dpcweb.com.

Except for the historical information contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially. These factors include governmental or other action relating to the Company's Chinese affiliate; the rate of customer demand for the Company's products; the Company's ability to successfully market new and existing products; its dependence on certain suppliers; domestic and foreign government regulation; its ability to keep abreast of technological innovations and to translate them into new products; competition; political and economic instability in certain markets including the movements of foreign currencies relative to the dollar; and other risks and uncertainties disclosed from time to time in the Company's SEC reports and filings.

###

DIAGNOSTIC PRODUCTS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(Amounts in Thousands, Except Per Share Data)

	Three Months Ended		Year Ended	
	December 31,		December 31,	
	2005	2004	2005	2004
SALES:				
Non-Affiliated Customers	\$ 115,879	\$ 110,840	\$ 456,465	\$ 413,952
Unconsolidated Affiliates	7,881	7,819	24,637	32,867
Total Sales	<u>123,760</u>	<u>118,659</u>	<u>481,102</u>	<u>446,819</u>
COST OF SALES				
	<u>58,031</u>	<u>58,010</u>	<u>212,690</u>	<u>200,049</u>
Gross Profit	65,729	60,649	268,412	246,770
OPERATING EXPENSES:				
Selling	20,062	19,461	79,406	74,599
Research and Development	14,455	11,639	52,097	45,277
General and Administrative	13,168	15,314	51,288	47,790
Gain on Sale of Product Line			(343)	
Equity in Income of Affiliates	<u>(1,933)</u>	<u>(1,914)</u>	<u>(9,821)</u>	<u>(8,451)</u>
OPERATING EXPENSES-NET	<u>45,752</u>	<u>44,500</u>	<u>172,627</u>	<u>159,215</u>
OPERATING INCOME	19,977	16,149	95,785	87,555
Interest/Other Income (Expense)-Net	<u>(235)</u>	<u>(357)</u>	<u>2,067</u>	<u>450</u>
INCOME BEFORE INCOME TAXES				
AND MINORITY INTEREST	19,742	15,792	97,852	88,005
PROVISION FOR INCOME TAXES	6,169	4,308	28,485	25,495
MINORITY INTEREST	490	341	2,214	775
NET INCOME	<u>\$ 13,083</u>	<u>\$ 11,143</u>	<u>\$ 67,153</u>	<u>\$ 61,735</u>
EARNINGS PER SHARE:				
BASIC	\$ 0.44	\$ 0.38	\$ 2.29	\$ 2.12
DILUTED	\$ 0.43	\$ 0.37	\$ 2.23	\$ 2.06
WEIGHTED AVERAGE SHARES OUTSTANDING:				
BASIC	29,494	29,181	29,371	29,082
DILUTED	30,147	30,016	30,138	29,910